SHARPE·IQStart free
Menu
TodayResearchEarningsToolsPricingSign in
NVCR reported third quarter 2026 results. The stock moved -7.5% on the print.
NVCRearnings

Earnings reactions, page 9

Novocure (NVCR) Q3 FY2026 earnings

October 29, 2026 · SharpeIQ Research Desk

Reported results

  • Total net revenues for the quarter were $193.4 million.
  • Gross margin for the quarter was 77%.
  • Net loss for the quarter was $10.4 million.
  • Adjusted EBITDA for the quarter was $15.7 million.
  • As of September 30, 2026, there were 5,260 total active patients on TTFields therapy globally.

Guidance

  • Full-year 2026 total net revenue: $736 million - $743 million
  • Full-year 2026 Adjusted EBITDA: $24 million - $34 million

Price and volatility reaction

The stock moved -7.5% on the print. No front-expiry chain was on file, so there is no straddle expected move. 30-day ATM implied volatility moved -26.4 vol points across the event (constant-maturity series — not the front-week crush).

MeasureValueBasis
Close before release14.172026-10-28
Close after release13.112026-10-29
Realised move-7.5%close to close
30d ATM IV change-26.4 vol ptsconstant-maturity series, not the front expiry
Price and volatility reaction. Closes either side of the release. No front-expiry chain on file for a straddle expected move. SharpeIQ — listed option chain and price_history

Source

The figures above come from the earnings release the company filed with the SEC on 2026-10-29 (8-K, Item 2.02). Read the original filing on sec.gov.

See this live in SharpeIQ

IV rank, historical IV and the single-ticker tools. The scanner and AI research are paid plans.

Open IV Rank →